Testicular dysfunction in Hodgkin's disease before and after treatment

Viviani, Simonetta; Ragni, G.; Santoro, Armando; Perotti, L.; Caccamo, E.; Negretti, E.; Valagussa, Pinuccia; Bonadonna, Gianni

doi:10.1016/0277-5379(91)90017-8

Cited by 149 publications

(56 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This corresponds to earlier studies on male fertility after treatment for HL, with higher rates of preserved fertility after treatment with ABVDlike regimens compared to MOPP-like regimens (Viviani et al, 1985;Anselmo et al, 1990;Viviani et al, 1991;Hill et al, 1995). Two male patients spontaneously fathered children after HDT.…”

Section: Discussionsupporting

confidence: 84%

“…Several studies have dealt with post-treatment gonadal function in HLSs, most of them with the end point of secondary amenorrhoea, spermatogenesis mirrored by sperm count analyses and the level of serum FSH (Viviani et al, 1985;Viviani et al, 1991;Hill et al, 1995;Behringer et al, 2005). For males, these analyses are a relatively appropriate parameter of fertility, whereas regular post-treatment menstruation does not equal ovulation and the possibility of pregnancy.…”

Section: Discussionmentioning

confidence: 99%

“…Most previous studies on fertility in Hodgkin's lymphoma survivors (HLSs) have addressed post-treatment spermatogenesis and secondary amenorrhea (Viviani et al, 1985(Viviani et al, , 1991Hill et al, 1995;Behringer et al, 2005). Although the number of achieved pregnancies and childbirths is sometimes reported in small series (Schilsky et al, 1981;Whitehead et al, 1983;Bonadonna et al, 1984;Anselmo et al, 1990), the selection of survivors attempting parenthood is not reported, with a few exceptions (Aisner et al, 1993;Hodgson et al, 2006).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Post-treatment parenthood in Hodgkin's lymphoma survivors

Kiserud

Fosså²,

Holte³

et al. 2007

Br J Cancer

View full text Add to dashboard Cite

Attempted and achieved post-treatment parenthood, with or without use of assisted reproduction techniques (ARTs), was assessed in Hodgkin's lymphoma survivors treated from 1971 -1998, aged below 50 (females) or 65 (males) at diagnosis, aged 18 to 75 at survey. Four treatment groups were constructed: radiotherapy only, low -, medium -and high gonadotoxic chemotherapy (with or without radiotherapy in the three chemotherapy groups). Using Kaplan -Meier estimates, log-rank tests and Cox regression analyses, factors influencing post-treatment parenthood were investigated, with birth of the first child after treatment as the end point. Fortyfive per cent (120/269) of males and 50% (91/184) of females reported attempted post-treatment parenthood. Of these, 76 (63%) males and 68 (75%) females had a child without use of ARTs. In addition 10 males and one female achieved post-treatment parenthood with use of ARTs. Treatment group was significantly associated with post-treatment parenthood, with highest probabilities after radiotherapy only and low gonadotoxic chemotherapy. In univariate analyses, age at diagnosis was a significant factor related to post-treatment parenthood in females.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Post-treatment parenthood in Hodgkin's lymphoma survivors

Kiserud

Fosså²,

Holte³

et al. 2007

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Chapman et al (1981) and others (e.g. Viviani et al, 1991) reported that sperm counts may be reduced before treatment. It is therefore uncertain whether the reduction in fertility is related to the disease rather than the treatment.…”

Section: Effects Of Treatment On Socioeconomic Factors Marriagementioning

confidence: 95%

Late effects of treatment for early-stage Hodgkin's disease

Brierley

Rathmell²,

Gospodarowicz³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

“…During recent years evidence has emerged that malignant lymphoma survivors may have subnormal serum levels of testosterone and/or elevated LH (Whitehead et al, 1982;Viviani et al, 1991;Howell et al, 1999) However, there are a few large studies confirming these findings, and even fewer studies are published which compare HLSs with NHLSs. On the other hand, endocrine hypogonadism may increase the risk of severe health problems such as premature osteoporosis and insulinresistance (Finkelstein et al, 1987;Howell et al, 2000;Greenfield et al, 2007).…”

mentioning

confidence: 99%

Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy

Kiserud¹,

Fosså

Bjøro

et al. 2009

Br J Cancer

View full text Add to dashboard Cite

Gonadal function was assessed in male lymphoma survivors based on serum hormone levels (LH, FSH, testosterone, SHBG), and was related to treatment, age and observation time. Male patients ⩽50 years at diagnosis treated for Hodgkin's (HL) and/or non-Hodgkin's lymphoma (NHL) at the Norwegian Radium Hospital from 1 January 1980 to 31 December 2002 were included. Five treatment groups were defined: 1: radiotherapy only and/or low gonadotoxic chemotherapy (both HL and NHL)(‘No/low'), 2: medium gonadotoxicity chemotherapy for NHL (‘med-NHL'), 3: medium gonadotoxicity chemotherapy for HL (‘med-HL'), 4: highly gonadotoxic chemotherapy for NHL (‘high-NHL'), 5: highly gonadotoxic chemotherapy for HL (‘high-HL'). Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: Testosterone below and/or LH above normal range (endocrine hypogonadism). One hundred and forty-four (49%) of the patients had normal gonadal hormones, 60 (20%) displayed exocrine hypogonadism and almost one-third ( n =90, 30%) had endocrine hypogonadism. Compared to those treated with no/low gonadotoxic chemotherapy patients from all other treatment groups had significantly elevated risk for exocrine hypogonadism. Patients from the other treatment groups, except those in the med-NHL group, also had significantly elevated risk for endocrine hypogonadism compared with the group treated with no/low gonadotoxic chemotherapy. Men aged above 50 years at survey were about five times more likely to have endocrine hypogonadism compared with those less than 40 years. Because of the adverse health effects following long-lasting endocrine hypogonadism, gonadal hormones should be assessed regularly in male lymphoma survivors, especially after treatment with alkylating agents and high-dose chemotherapy with autologous stem cell support and in male patients who are 50 years and older.

show abstract

Testicular dysfunction in Hodgkin's disease before and after treatment

Cited by 149 publications

References 21 publications

Post-treatment parenthood in Hodgkin's lymphoma survivors

Post-treatment parenthood in Hodgkin's lymphoma survivors

Late effects of treatment for early-stage Hodgkin's disease

Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy

Contact Info

Product

Resources

About